Gland Pharma adds over 30% in ten days

Image
Capital Market
Last Updated : Dec 07 2020 | 2:04 PM IST

Gland Pharma jumped 8.88% to Rs 2,372 as the scrip resumed its uptrend after a day's breather.

The scrip was listed on the stock exchanges on 23 November 2020 at Rs at Rs 1701, a premium of 13.4% to the initial public offer (IPO) price of Rs 1500. On that day it closed 7.02% higher at Rs 1,820.45. Since then, the stock has jumped 30.30% in ten sessions to currently trade at Rs 2,372.

The IPO of Gland Pharma was subscribed 2.06 times. The issue opened for bidding on 9 November 2020 and it closed on 11 November 2020. The price band for the IPO was set at Rs 1490-1500 per share.

The company proposes to utilise the net proceeds of the fresh issue towards funding incremental working capital requirements; funding capital expenditure requirements; and general corporate purposes.

The company recorded net profit of Rs 313.59 crore and total income of Rs 916.28 crore in the quarter ended on 30 June 2020.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 07 2020 | 1:43 PM IST

Next Story